4-Bromofentanyl (para-bromofentanyl) is an opioid analgesic drug that is an analog of fentanyl and has been sold as a designer drug,[1] first identified in Pennsylvania in the US in March 2020.[2]

4-Bromofentanyl
Legal status
Legal status
Identifiers
  • N-(4-bromophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H27BrN2O
Molar mass415.375 g·mol−1
3D model (JSmol)
  • CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=C(C=C3)Br
  • InChI=1S/C22H27BrN2O/c1-2-22(26)25(20-10-8-19(23)9-11-20)21-13-16-24(17-14-21)15-12-18-6-4-3-5-7-18/h3-11,21H,2,12-17H2,1H3
  • Key:UTXQWNZEVFXSIA-UHFFFAOYSA-N

Effects

edit

The effects of fentanyl analogs are similar to those of fentanyl itself, which include potent sedation and analgesia, along with side effects such as itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed thousands of people throughout the world since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.[3] A new wave of fentanyl analogues and associated deaths began in around 2014 in the US, and have continued to grow in prevalence; especially since 2016 these drugs have been responsible for hundreds of overdose deaths every week.[4]

edit

4-Bromofentanyl is a Schedule I controlled drug in the United States under the fentanyl analogue provisions introduced in 2018, despite not being specifically listed in its own right.[5]

See also

edit

References

edit
  1. ^ Feeney W, Moorthy AS, Sisco E (December 2020). "Spectral trends in GC-EI-MS data obtained from the SWGDRUG mass spectral library and literature: A resource for the identification of unknown compounds". Forensic Chemistry. 31. Amsterdam, Netherlands. doi:10.1016/j.forc.2022.100459. PMC 9793444. PMID 36578315.
  2. ^ "Bromofentanyl Analytical Report" (PDF). Novel Psychoactive Substances (NPS) Discovery. Willow Grove, PA: The Center for Forensic Science Research & Education (CFSRE). 17 December 2020.
  3. ^ Mounteney J, Giraudon I, Denissov G, Griffiths P (July 2015). "Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe". The International Journal on Drug Policy. 26 (7): 626–631. doi:10.1016/j.drugpo.2015.04.003. PMID 25976511.
  4. ^ Armenian P, Vo KT, Barr-Walker J, Lynch KL (May 2018). "Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review". Neuropharmacology. 134 (Pt A): 121–132. doi:10.1016/j.neuropharm.2017.10.016. PMID 29042317. S2CID 21404877.
  5. ^ Weedn VW, Elizabeth Zaney M, McCord B, Lurie I, Baker A (July 2021). "Fentanyl-related substance scheduling as an effective drug control strategy". Journal of Forensic Sciences. 66 (4): 1186–1200. doi:10.1111/1556-4029.14712. PMC 8360110. PMID 33951192.